Cloning natural product biosynthetic gene clusters from cultured or uncultured sources and 16 their subsequent expression by genetically tractable heterologous hosts is an essential strategy for the 17 elucidation and characterisation of novel microbial natural products. The availability of suitable 18 expression hosts is a critical aspect of this workflow. In this work, we mutagenised five endogenous 19 biosynthetic gene clusters from Streptomyces albus S4, which reduced the complexity of chemical 20 extracts generated from the strain and eliminated antifungal and antibacterial bioactivity. We showed 21 that the resulting quintuple mutant can express foreign BGCs by heterologously producing 22 actinorhodin, cinnamycin and prunustatin. We envisage that our strain will be a useful addition to the 23 growing suite of heterologous expression hosts available for exploring microbial secondary 24 metabolism. 25
Introduction 26
The majority of clinically used antibiotics are derived from natural products produced by 27
Streptomyces species and other closely related Actinobacteria, which were introduced into the clinic 28 during a 'golden era' of antibiotic discovery spanning 1940-1960 [1] . The utility of these agents has 29 been eroded over the last half-century due to misuse. As a consequence, there is now an urgent need 30 to discover new antibiotics to treat bacterial infections, particularly those caused by drug-resistant 31
'ESKAPE' pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 32
Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) [2] . Growing concerns 33 about resistance to antibacterial agents combined with the failure to find new leads from the screening 34 of large libraries of synthetic compounds has led to a renewed interest in natural products discovery 35
[3]. This renaissance has been fuelled to a large extent by the relatively inexpensive cost to sequence 36 genomes of strains that produce promising bioactive small molecules. For example, there are 37 currently >750 streptomycete genomes available in GenBank compared to four years ago when there 38 were only ~150 [4] . Analysis of these genome sequences have illuminated the exciting prospect that 39 the majority of microbial secondary metabolism has yet to be uncovered [5] . 40
Further study of potentially interesting natural product biosynthetic pathways is often 41 precluded by the poor growth characteristics of the strain and/or genetic intractability. Therefore, a 42 heterologous expression strategy using a faster-growing and genetically tractable host is frequently 43 adopted and indeed has become the method of choice for accessing new natural products and 44 interrogating their biosynthesis. Technology for generating and screening large-insert genomic 45 libraries (e.g. cosmid, BAC and PAC libraries) to obtain biosynthetic gene cluster (BGC) clones are 46 well established [6, 7] . These approaches are in the process of being superseded by recombination-47 chemical extracts prepared from culture supernatants of S. albus S4 wild-type or ∆5 cultivated in 108 liquid MS against Candida albicans and Micrococcus luteus, which revealed that extracts from the 109 ∆5 strain were not bioactive (Fig. 2CD) . 110
Chromatographic profile of ∆5. Chemical extracts generated from S. albus S4 wild-type are 111 complex and chromatographs are dominated by candicidins and antimycins when using a standard 112 aqueous/organic phase gradient of 5-95% acetonitrile or methanol [26, 31] . In order to assess to what 113 extent this complexity was reduced in extracts generated from the ∆5 mutant, we cultivated S4 wild-114 type and ∆5 using liquid MS and performed an ethyl acetate extraction of the resulting clarified 115 culture supernatant. Next, extracts were analysed by HPLC, which as anticipated, revealed that the 116 extracts generated from the ∆5 were far less complex than those generated from the wild-type strain 117 (Fig. 3) . The cleaner chromatographic background of the S. albus S4 ∆5 strain will simplify detection 118 of heterologously produced natural products by HPLC or LC-MS and ease their subsequent 119
purification. 120
Heterologous production of actinorhodin, cinnamycin and prunustatin. As a proof of 121 principle to demonstrate that S4 ∆5 can produce natural products encoded by other taxa, we 122 introduced three foreign BGCs: the actinorhodin BGC from S. coelicolor A3(2), the cinnamycin BGC 123 from S. cinnamoneus DSM 40646 and the neoantimycin/prunustatin BGC from S. orinoci B-NRRL 124 3379 [20, 32, 33] . These BGCs were selected in part due to accessibility, but also because they 125 comprised three different biosynthetic systems. Actinorhodin is a type II polyketide antibacterial, 126 cinnamycin is a ribosomally synthesised and post-translationally modified peptide antibacterial and 127 neoantimycin/prunustatin is a hybrid non-ribosomal peptide / polyketide anti-cancer compound. 128
Recombinant strains harbouring these BGCs were generated and cultivated using MS agar or TSB 129 for seven days. Next, chemical extracts were prepared from the ∆5/Act, ∆5/Cin, ∆5/Prun strains and 130 their parent and subsequently analysed by LC-HRMS (Fig. 4) . Inspection of the resulting data 131 revealed the presence of compounds consistent with ɣ-actinorhodin, cinnamycin and prunustatin in 132 chemical extracts prepared from ∆5/Act, ∆5/Cin, ∆5/Prun, respectively and importantly, their absencefrom the ∆5 parental strain. These data indicate that S. albus S4 ∆5 is capable of heterologous 134 expressing foreign BGCs from classes of varying biosynthetic logic. 135 Summary and concluding perspectives. We have constructed a strain of S. albus S4 in 136 which the antimycin, candicidin, albaflavenone, surugamide and fredericamycin BGCs have been 137 mutated. We showed that the resulting strain, S. albus S4 ∆5, possessed a simpler chromatographic 138 profile and did not possess antibacterial or antifungal activity using the growth media tested and also 139 demonstrated that it could serve as a surrogate host for the production of actinorhodin, cinnamycin 140 and prunustatin. Interestingly, during the course of our study we also tried to heterologously produce 141 bicyclomycin and methylenomycin, but were unable to detect either metabolite by LC-HRMS. The 142 unsuccessful attempt to heterologously produce bicyclomycin and methylenomycin underscores a 143 key consideration for heterologous expression studies -host selection. For instance, S. coelicolor is 144 a native producer of methylenomycin and was recently used as a host for bicyclomycin production 145
[34], however it will not produce neoantimycin/prunustatin unless the biosynthetic genes are 146 artificially expressed from constitutive promoters [33] . Indeed, there is no panacea in terms of a 147 heterologous expression host, each one being somewhat enigmatic with peculiarities rooted in 148 primary metabolism (i.e. precursor and co-factor supply) or promoter recognition elements. It is 149 therefore advantageous and indeed wise when pursuing heterologous expression of a BGC to cast a 150 wide net and screen multiple hosts. The S. albus S4 ∆5 strain constructed here will hopefully be a 151 useful tool to that end.
Materials and methods 153
Growth media, strains and reagents. Escherichia coli strains were cultivated using Lennox 154 agar (LA) or broth (LB) and Streptomyces strains were cultured using mannitol-soya flour (MS) agar, 155 tryptic soy broth (TSB) or agar (TSA) [35] . Culture media was supplemented with antibiotics as 156 required at the following concentrations: apramycin (50 μg/ml), carbenicillin (100 μg/ml), 157 hygromycin (75 μg/ml), kanamycin (50 μg/ml), nalidixic acid (25 μg/ml). Enzymes were purchased 158 from New England Biolabs and oligonucleotides were purchased from Integrated DNA 159
Technologies. The bacterial strains, cosmids and plasmids used in this study are described in Table  160 S1 and the oligonucleotides are described in Table S2 . 161
Mutagenesis of biosynthetic gene clusters. In order to delete the ant BGC, the antF gene on 162 S4 Cosmid213 [31] was replaced with the apramycin resistance cassette from pIJ773 using PCR 163 targeted mutagenesis as previously described [36] . The mutated cosmid was used to generate an 164 apramycin resistant S. albus S4 ∆antF strain. Next, antABCDEFGHIJKLMNO on Cosmid213 were 165 replaced with the apramycin resistance cassette in the same manner as above and subsequently 166 removed by the Flp recombinase, after which the bla gene was replaced with the hygromycin 167 resistance cassette also harbouring an oriT from pIJ10701 as previously described [36] to result in 168 Cosmid213 ∆antFLP B2H. This cosmid was mobilised to S. albus S4 ∆antF and a single hygromycin 169 resistant transconjugant was selected and subsequently passaged twice in the absence of selection 170 prior to replica plate identification of an apramycin sensitive and hygromycin sensitive isolate that 171 we named S. albus S4 ∆1. The integrity of this strain was confirmed by PCR using primers RFS236 172 and RFS237. 173
The can BGC was mutated using the previously constructed fscC (STRS4_02234) deletion 174 plasmid, pKC1132-UpDn [26]. pKC1132-UpDn was mobilised to S. albus S4 ∆1 strain and a single 175 apramycin resistant transconjugant was selected and passaged as above until an apramycin-sensitive 176 isolate was identified, which we named S. albus S4 ∆2.
The surugamide, fredericamycin and albaflavenone BGCs were mutated using the 178 pCRISPomyces-2 system describe previously [37] . First, a single-guide RNA protospacer was 179 generated by annealing oligonucleotides EH_S9 and EH_S10 (surugamide), EH_S3 and EH_S4 180 (albaflavenone) and EH_S7 and EH_S8 (fredericamycin); the resulting DNA fragments were cloned 181 into the BbsI site of pCRISPomyces-2 by Golden Gate Assembly. Second, two overlapping DNA 182 fragments representing a homology-directed repair template were generated by PCR using the 183 primers listed in Table S2 . The overlapping PCR products were subsequently cloned into the XbaI 184 site of protospacer-containing pCRISPomyces-2 plasmid using the NEBbuilder HiFi DNA assembly 185 kit. The resulting CRISPR/Cas9 editing plasmids, pCRISPomyces-2-sur, pCRISPomyces-2-alb, 186 pCRISPomyces-2-fdm were sequentially mobilised to Streptomyces and cured as described 187 previously [38] and schematically illustrated in Figure S1 to result in the quintuple mutant strain 188 described in this study, S. albus S4 ∆5. placed into an Erlenmeyer flask and metabolites extracted with ethyl acetate (100 ml) for 24 hrs. The 215 ethyl acetate extract was decanted and concentrated in vacuo and the dried residue was resuspended 216 in 100% methanol (500 μl). For the production of cinnamycin, S. albus S4 ∆5 and ∆5/Cin strains 217 were cultured in 50 ml TSB for 7 days at 30 °C. The resulting mycelia was collected by centrifugation 218 and extracted with 100% methanol (45 ml) for 4 hours. The methanolic extracts were evaporated to 219 dryness in vacuo and resuspended in 100% methanol (500 μl) as above. Equal volumes of methanolic 220 extract for three independently cultivated replicates of ∆5, ∆5/Act, ∆5/Cin, ∆5/Prun were pooled and 221 centrifuged for 10 minutes at 16,000 x g to remove insoluble material prior to analysis by high 222 resolution electrospray ionization liquid chromatography mass spectrometry (LC-HRMS). Only the 223 supernatant (2 μl) was injected into a Bruker MaXis Impact TOF mass spectrometer and equipped 224 with a Dionex Ultimate 3000 HPLC exactly as previously described [13] . 
